Patent 10577317 was granted and assigned to Sunovion Pharmaceuticals Inc. on March, 2020 by the United States Patent and Trademark Office.
The various aspects present inventions provide various crystalline forms of (S)-(−)-amisulpride, (R)-(+)-amisulpride, and solvates thereof and methods of making same. In various aspects, the inventions also provide methods of resolving racemic amisulpride.